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Abstract The relationship among the real-time trafficking of
lung metastatic B16BL6 cells, metastatic potential, and the
injected number of the cells was examined, since the smaller the
number of tumor cells injected, the more clearly the immune
defense may be observed. When 1U106 or 1U105 B16BL6 cells
were injected into mice via the tail vein, both numbers of cells
accumulated in the lung at a similar rate: there was an
approximately 10-fold difference in the number of accumulated
cells between the two doses. Elimination from the lung was not
dependent on the cell number but on the proportion of
accumulated cells. However, the injection of 1U104 cells resulted
in lung accumulation less than one-tenth of that obtained with
1U105 cell injection. Metastasis was observed when 1U105 or
1U106 B16BL6 cells were injected, but not after injection of
1U104 cells. To clarify the roles of the immune defense system at
the initial phase of metastasis, we challenged macrophage-
depleted mice with 1U104 tumor cells. Treatment of mice with 2-
chloroadenosine prior to the tumor cell challenge cancelled the
suppression of not only metastasis but also the lung accumula-
tion. Furthermore, the administration of 2-chloroadenosine
following the tumor cell challenge had little effect on the
metastatic potential. These results suggest that the immune
surveillance whose action was obvious at the low dose of
challenged tumor cells functions strongly at the initial phase
but not at the advanced stages of the metastatic process, and that
macrophages play an important role in the suppression of
metastasis.
z 2000 Federation of European Biochemical Societies.
Key words: Metastasis ; Immune surveillance; Macrophage;
B16BL6; Positron emission tomography;
Tumor cell tra⁄cking
1. Introduction
Metastasis occurs through a complex cascade of events in-
cluding dissociation of cancerous cells from the primary site,
intravasation, adhesion to the vascular endothelium of the
target organ, extravasation, and growth at the colonization
site [1^3]. On the other hand, host resistance mechanisms
for limiting the dissemination and rapid progressive out-
growth of tumor cells may come into play to prevent meta-
stasis. For example, even after surgical removal of the primary
tumor, substantial numbers of viable tumor cells are detected
in the circulation whereas this ¢nding does not correlate well
with subsequent development of detectable metastases [4]. It
has also been empirically shown that a certain number of
metastatic tumor cells is required for obtaining metastatic
foci, and metastasis is not observed after inoculation of the
smaller number of cells in experimental metastasis models.
Therefore, development of metastases may be the end result
of a sequential process including the ability of the metastatic
cells to circumvent the immune surveillance of the host.
Macrophages and NK cells are thought to be the ¢rst line
of defense in target organs such as the liver and lung
against invading metastatic tumor cells [5], and come into
play following the immune reaction involving speci¢c T and
B lymphocytes. However, it is not clear when macrophages
are able to exclude the metastatic tumor cells in the course of
metastasis.
Due to technological developments, we are now able to
obtain positron-labeled compounds of more than 1 GBq/ml
for labeling tumor cells. Thus now we can examine real-time
tumor cell tra⁄cking non-invasively with as few as 104 cells
after positron labeling of the cells by positron emission to-
mography (PET). In this study, we investigated the tra⁄cking
of lung metastatic B16BL6 cells in relation to the number of
injected cells, since the smaller the number of tumor cells in-
oculated, the more clearly the immune defense system may
work. We observed that fast elimination of metastatic tumor
cells from the target tissue, lung, resulted in suppression of
metastatic potential when a small number of the cells was
injected. In addition, to clarify the roles of immune surveil-
lance against metastasis, we investigated the metastatic poten-
tial and tra⁄cking of tumor cells in mice treated with 2-
chloroadenosine (2-ClAd). This compound is known to exert
a lethal e¡ect on mouse adherent peritoneal cells in vitro with-
out a¡ecting mouse lymphocytes and polymorphonuclear cells
[6], and is known to enhance lung metastasis of M109 tumor
cells after i.p. injection [7]. The results indicate the importance
of immune surveillance at the early phase of metastasis.
2. Materials and methods
2.1. Cell culture and determination of metastatic potential
B16BL6 cells, a highly lung metastatic subline of murine B16 mel-
anoma, were cultured in Dulbecco’s modi¢ed Eagle’s medium (DME)
and Ham’s F12 (1:1) medium (DME/F12M) supplemented with 10%
fetal bovine serum (JRH Biosciences, Lenexa, KS, USA) under a
humidi¢ed atmosphere of 5% CO2 in air. The metastatic potential
of these cells was determined after injection of 1U104, 1U105, or
1U106 cells/0.2 ml via the tail vein of 8-week-old male C57BL/6
mice (¢ve per group, Japan SLC Inc., Hamamatsu, Japan). Coloniza-
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Fig. 1. In vivo tra⁄cking of [2-18F]FDG-labeled B16BL6 cells. a: [2-18F]FDG-labeled B16BL6 cells (1U105 cells/0.2 ml) were injected via the
tail vein of C57BL/6 mice. Biodistribution during 30 min after administration of the cells was imaged by PET, and corresponding X-ray CT
images (depicted from [9]) are shown with a slice aperture of 3.25 mm. Twelve slices from the tail side (upper left) to the head side (lower
right) are shown. The experiment was repeated twice, and similar results were obtained in separate experiments, although the images represent
a typical result obtained from a single animal. Gradation was corrected to be comparable between all images. Li, liver; Lu, lung; K, kidney.
b: B16BL6 cells (1U106 cells including 1U104 [2-18F]FDG-labeled cells, 1U105 cells including 1U104 [2-18F]FDG-labeled cells, and 1U104
[2-18F]FDG-labeled cells) were injected via the tail vein. The emission scan of PET was started immediately after injection of the cells and was
performed for 90 min. Every 15-min accumulation of B16BL6 cells in the lung is shown.
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tion of B16BL6 cells in lungs and other tissues was determined at day
14 after injection. The animals were cared for according to the animal
facility guidelines of the University of Shizuoka.
2.2. Preparation of cell suspensions for PET analysis
The cells were labeled with [2-18F]2-£uoro-2-deoxy-D-glucose
([2-18F]FDG) as described previously [8,9]. In brief, B16BL6 cells
were washed with glucose-free medium and incubated with 1 GBq
of [2-18F]FDG for 30 min at 37‡C. After the free [2-18F]FDG had
been washed away, the cells were removed from the plate with EDTA
solution to obtain a single cell suspension. Preparation of cell suspen-
sion was as follows: 1U104 18F-labeled cells alone in 0.2 ml of me-
dium or the cells were mixed with 9-fold and 99-fold excess of cold
cells, resulting in total cell numbers of 1U105 cells and 1U106 cells in
0.2 ml of medium, respectively. Viability of the labeled cells was
determined by the trypan blue dye exclusion method and was greater
than 90% through the entire experiment.
2.3. PET analysis
The animal PET camera (Hamamatsu Photonics, SHR-2000) used
in the experiment has an e¡ective slice aperture of 3.25 mm and a
resolution of 2.7 mm. After a 30-min transmission scan with 18.5
MBq of 68Ge/68Ga ring source, 18F-labeled single cell suspension
was injected into 8-week-old C57BL/6 male mice for B16BL6 cells
via the tail vein under anesthesia with sodium pentobarbital. The
emission scan of PET was started immediately after injection of the
cells and performed for 90 min. The initial 60 frames were taken one
every 1 min; and the next 12 frames, one every 2.5 min. Thus 72
frames were taken during a PET scan. PET images were simultane-
ously obtained in 14 slices where the mouse location was adjusted at
the xiphisternum. The radioactivity in the form of coincidence gamma
photons was measured and converted to Bq/cm3 of tissue volume by
calibration after correction for decay and attenuation. Time^activity
curves were obtained from mean pixel radioactivity in the region of
interest (ROI) of the composed PET images where the injected dose
was calibrated as 740 kBq. Each experiment was repeated at least
twice, and similar results were obtained in repeated experiments,
although each ¢gure represents a typical result obtained from a single
animal.
3. Results
3.1. Tra⁄cking of B16BL6 cells after injection of various
numbers of the cells
The real-time tra⁄cking of B16BL6 cells after injection via
the tail vein of C57BL/6 mice was analyzed by PET (Fig. 1).
PET images indicated that most of the B16BL6 cells accumu-
lated in the lung, and that essentially none of cells accumu-
lated speci¢cally in heart, kidneys, spleen, or other tissues
examined except liver, at which organ a small number of cells
were accumulated. The results are consistent with the data
previously reported [9]. The PET images indicated that the
accumulation of cells in lung after the injection of 1U106 or
1U105 cells/0.2 ml was more intense than that after injection
of 1U104 cells/0.2 ml, and that the cells were eliminated from
the target organ faster in the latter case than in the former.
The time^activity curve of the accumulation of B16BL6 cells
in the lung is shown in Fig. 2. The results indicated that the
accumulation of cells after injection with 1U106 and 1U105
cells/0.2 ml was more intense than that with 1U104 cells/0.2
ml starting immediately after the injection. Since 99- and
9-fold excesses of cold cells were present in the samples of
1U106 and 1U105 cell suspensions, respectively, the actual
cell numbers for accumulation and elimination numbers for
these two doses were 100- and 10-fold greater than those after
injection with 1U104 cells (Fig. 2b).
3.2. Metastatic potential of B16BL6 cells in lung after injection
of various numbers of the cells
To examine the correlation between accumulation of tumor
cells in the target tissue and metastatic potential, we injected
1U106, 1U105, and 1U104 B16BL6 cells/0.2 ml into mice.
Lung metastatic foci of B16BL6 cells were observed after in-
jection at 1U106 or 1U105 cells (Table 1). In contrast, the
injection of 1U104 cells/0.2 ml resulted in no metastatic foci
at all, even though the number of cells injected was 10% of
that in the case of the injection with 1U105 cells. Interest-
ingly, injection of 1U106 cells caused not only lung metastatic
foci but also liver metastatic ones. These results indicate that a
certain critical number of metastatic tumor cells is initially
required for establishing metastatic colonization in this exper-
Fig. 2. Time^activity curves of 18F accumulation in lung after injec-
tion of [2-18F]FDG-labeled B16BL6 cells. In vivo tra⁄cking of
[2-18F]FDG-labeled B16BL6 cells injected via the tail vein was ex-
amined as described in the legend to Fig. 1. a: Time^activity curves
of 18F accumulation in the lung were determined by PET analysis.
a, injected with 1U106 cells ; b, 1U105 cells; E, 1U104 cells. b:
Relative cell accumulation calculated from panel a, where the high-
est accumulation after injection of 1U106 cells is given as 100.
Dashed line shows 1/10 and 1/100 amounts of the relative accumu-
lation of cells after injection of 1U106 cells. a, injected with 1U106
cells ; b, 1U105 cells ; E, 1U104 cells.
Table 1
Experimental metastasis produced by various numbers of B16BL6
cells
Cell number Number of metastatic colonies
Lung Liver
1U104 cells 0, 0, 0, 0, 0 0, 0, 0, 0, 0
1U105 cells 174, 173, 170, 165, 148 1, 0, 0, 0, 0
1U106 cells s 300, s 300, s 300, s 300, s 300 14, 11, 10, 8, 3
Various numbers of B16BL6 melanoma cells (1U104 cells/0.2 ml,
1U105 cells/0.2 ml or 1U106 cells/0.2 ml) were injected via the tail
vein of male C57BL/6 mice (n = 5), and the number of metastases in
the lung and liver was counted 14 days after tumor inoculation.
Table 2
E¡ect of 2-ClAd treatment on metastasis of B16BL6 cells
Mice Number of metastatic colonies
Lung Liver
Non-treated 0, 0, 0, 0, 0 0, 0, 0, 0, 0
2-ClAd-pretreated 37, 11, 3, 3, 1 10, 4, 4, 0, 0
2-ClAd-posttreated 1, 0, 0, 0, 0 0, 0, 0, 0, 0
2-ClAd at 25 mg/kg was administered i.p. 2 days before and after
the inoculation of B16BL6 cells (1U104 cells/0.2 ml) via the tail
vein of C57BL/6 mice (n = 5). The number of metastatic foci in the
lung and liver was counted 14 days after tumor inoculation.
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imental metastatic model: the critical number may be between
104 and 105 in the present metastatic model.
3.3. E¡ect of 2-ClAd treatment on metastatic potential and
tumor cell tra⁄cking
Since macrophages in the circulation or resident in the spe-
ci¢c organs play an important role in immune surveillance
against metastasis, we investigated macrophage-mediated re-
sistance to metastasis by use of macrophage-depleted animals.
Table 2 shows the metastatic potential of B16BL6 melanoma
cells in relation to the timing of 2-ClAd treatment and tumor
challenge. The most dramatic increase in metastasis was ob-
served in mice treated with 2-ClAd prior to the tumor inocu-
lation. This observation is consistent with the previous study
reported by Zhang and coworkers [10]. In addition, metastatic
foci could be detected in the liver even after the injection of
1U104 cells. In contrast, administration of 2-ClAd 2 days
after the tumor inoculation had little e¡ect on the coloniza-
tion caused by B16BL6 cells.
On the basis of the results shown above, we employed PET
analysis to determine the real-time tra⁄cking of the tumor
cells in 2-ClAd-pretreated mice. As shown in Fig. 3, the ac-
cumulation of B16BL6 cells in the lungs of 2-ClAd-pretreated
mice was higher than that in the non-treated ones after the
cells had been injected via the tail vein. In addition, the ac-
cumulation of the cells in liver was also increased for 2-ClAd-
pretreated mice. The lung accumulation pattern of 1U104
cells injected into the 2-ClAd-pretreated mice was similar to
that of 1U106 cells injected into non-treated mice shown in
Fig. 2 (Fig. 4). Therefore, these results indicate that macro-
phages may in£uence tumor metastasis through a¡ecting tu-
mor cell tra⁄cking at the initial phase of hematogenous dis-
semination, presumably by their ability to eliminate directly
the tumor cells from the circulation in the blood or at the
capillary beds in the target organ.
Fig. 3. In vivo tra⁄cking of B16BL6 cells in mice pretreated with 2-ClAd. Eight-week-old BALB/c mice were i.p. pretreated with 25 mg/kg of
2-ClAd or phosphate-bu¡ered saline (PBS). Two days later the mice were injected with [2-18F]FDG-labeled B16BL6 cells (1U104 cells/0.2 ml)
via the tail vein. The emission scan of PET was performed for 90 min. Every 15-min accumulation of B16BL6 cells in the lung (a) and liver
(b) is shown.
Fig. 4. Time^activity curves of 18F accumulation in lung and liver
after injection of [2-18F]FDG-labeled B16BL6 cells into mice pre-
treated with 2-ClAd. Tra⁄cking of [2-18F]FDG-labeled B16BL6
cells was examined by PET after injection of the cells into i.p. pre-
treated with 25 mg/kg of 2-ClAd (b) or PBS (a) as described in the
legend to Fig. 3. The time^activity curves of 18F in the lung (a) and
liver (b) are shown.
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4. Discussion
In the early stage of blood-borne metastasis, metastatic tu-
mor cells intravasating from the primary site may adhere to
and extravasate through the vascular endothelium of the tar-
get organ [11^13], and this adhesion process is thought to be a
prerequisite for metastasis establishment. The interaction of
metastatic cells with the endothelium may be initiated via the
interaction between selectin molecules and their ligands such
as sialylglyco-conjugates [14,15]. During circulation and the
adhesion of tumor cells, host cells, such as lymphocytes,
NK cells, and monocytes, which are important for the disrup-
tion of tumor cells [16^19], may interact with them. Therefore,
the ability of the metastatic cells to circumvent the immune
surveillance of the host organ is important for the establish-
ment of metastases.
In the present study, we examined the tra⁄cking of B16BL6
cells after injection via the tail by PET analysis. The analysis
re£ects physiological phenomena under actual blood £ow con-
ditions where the £uid mechanical forces are taken into ac-
count in the microcapillary environment [9,20]. As shown in
Fig. 1, accumulation of 18F-labeled cells in lung, the target
organ, after injection of 1U106 cells including 1U104 18F-
labeled cells was quite similar to that after injection of
1U105 cells including 1U104 18F-labeled cells. These results
indicate that the amount of tumor cells accumulated in a
target organ does not depend on the number of the cells in-
jected but on the proportion of the cells : when 10-fold cells
were injected, about 10-fold cells accumulated. Similar phe-
nomena are usually observed in cell adhesion assays in vitro:
the percent adhesion of certain tumor cells to endothelial cells
or extracellular matrix components is little dependent on cell
number. A correlation between the number of tumor cells
injected and the accumulation of the cells in the target organ
was only observed when 1U106 and 1U105 cells were in-
jected, and the accumulation rate decreased markedly after
injection of 1U104 18F-labeled cells.
Since the e¡ect of host cells against metastatic tumor cells
may be more obvious when the number of metastatic cells is
small enough to be attacked, we investigated the metastatic
potential in relation to the number of challenging tumor cells
in the experimental metastatic model. When 1U106 or 1U105
metastatic tumor cells were injected, apparent metastasis was
observed. In contrast, metastasis was not demonstrated after
injection of 1U104 cells : if one-tenth of the population of the
case 1U105 cells injected, some metastatic foci would have
been detectable. These data suggest that the formation of
metastases requires a certain number of tumor cells for avoid-
ance of the host defense mounted by cells such as NK cells
and monocytes, and that host immune surveillance in£uences
the metastatic spread of tumors during the initial phase of
metastasis.
The presumption of tumor cell tra⁄cking during metastasis
has not been fully con¢rmed. In addition, it is unclear when
macrophages can in£uence the metastatic tumor cells in the
process of metastasis under actual blood £ow conditions.
Thus, we next examined the e¡ect of the immune defense
system such as the function of macrophages on tumor cell
tra⁄cking in relation to tumor challenge and the time of
2-ClAd treatment. As shown in Table 2, the most drastic
increase in metastasis occurred when mice were treated with
2-ClAd 2 days prior to tumor inoculation. This result also
correlated well with the tra⁄cking of the cells : PET analysis
demonstrated a marked increase in the accumulation of
B16BL6 cells in the lungs of mice pretreated with 2-ClAd.
In addition, 2-ClAd pretreatment caused the enhanced accu-
mulation of the cells in liver, which phenomenon is consistent
with the liver colonization of B16BL6 cells shown in Table 2.
In contrast, administration of 2-ClAd following tumor inocu-
lation had little or no e¡ect on metastasis. This fact may be
explained as follows: once tumor cells have invaded the pa-
renchyma of the target organ, macrophages would have less
in£uence on the tumor cells. Thus, macrophages could elimi-
nate metastatic tumor cells from the bloodstream or from the
target organ only in the early phase of the metastatic process.
Moreover, it is known that tumor cells grow and secrete trans-
forming growth factor L and prostaglandin E2 in the ad-
vanced stages of the metastatic process, both of which are
known to reduce the cytotoxic action of macrophages in the
tumor area [5].
Our present data demonstrated that the drastically lower
metastatic potential of 1U104 cell injection in comparison
with that of the higher numbers of injected cells correlated
with the accumulation of the cells in the target organ as de-
termined by the PET analysis. This result might be attribut-
able to the removal of this smaller number of tumor cells by
the immune defense system such as the function of macro-
phages. The cytotoxic/cytostatic activity of macrophages is
attributed to the up-regulation of inducible nitric oxide syn-
thase and the production of nitric oxide (NO) [21^23], phag-
ocytic actions [24], and the action mediated by membrane-
bound tumor necrosis factor K [25]. However, the elimination
of tumor cells seemed to be quite fast compared with the
reported time course of in vitro cell lysis. Hence, NO may
not be responsible for the early elimination of tumor cells
by macrophages in vivo.
Taken together, the data presented here allow us to con-
clude that immune surveillance against metastatic tumor cells
functions strongly at the initial phase of the metastatic process
but not at the advanced stage, and that macrophages, at least,
may play an important role in this immune surveillance.
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